Earlier this week, HRSA held a webinar focused on how monoclonal antibody therapeutics can help prevent serious illness from COVID-19. It featured Michael R. Anderson, MD, a Senior Advisor to HHS’ Assistant Secretary for Preparedness and Response (ASPR).
More about the Webinar
In the continued fight against COVID-19, we have seen how important monoclonal antibody therapeutics are in helping prevent serious illness. As viral variants arise and spread, it is increasingly critical that health care providers have the latest treatment information at their fingertips. Dr. Anderson shared updates on available COVID-19 therapeutics including efficacy, new administration routes and novel treatments in the pipeline, reimbursement resources, and provider and patient tools and fact sheets. Dr. Anderson and HRSA representatives answered providers’ questions about these important COVID-19 therapies. Questions? Contact Dr. Anderson and his team.
Learn more about monoclonal antibody therapeutics on ASPR’s website: